Livforsakringsbolaget Skandia Omsesidigt reduced its position in shares of Metlife Inc (NYSE:MET) by 11.4% in the fourth quarter, HoldingsChannel.com reports. The firm owned 52,748 shares of the financial services provider’s stock after selling 6,800 shares during the quarter. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Metlife were worth $2,667,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Beach Investment Management LLC. bought a new position in shares of Metlife during the 2nd quarter valued at approximately $1,471,000. Fiduciary Trust Co. grew its stake in shares of Metlife by 15.1% during the 2nd quarter. Fiduciary Trust Co. now owns 12,077 shares of the financial services provider’s stock valued at $664,000 after acquiring an additional 1,580 shares during the period. WMS Partners LLC grew its stake in shares of Metlife by 4.4% during the 2nd quarter. WMS Partners LLC now owns 4,429 shares of the financial services provider’s stock valued at $243,000 after acquiring an additional 188 shares during the period. Freestone Capital Holdings LLC grew its stake in shares of Metlife by 3.1% during the 2nd quarter. Freestone Capital Holdings LLC now owns 22,746 shares of the financial services provider’s stock valued at $1,250,000 after acquiring an additional 678 shares during the period. Finally, IFM Investors Pty Ltd grew its stake in shares of Metlife by 114.8% during the 2nd quarter. IFM Investors Pty Ltd now owns 25,375 shares of the financial services provider’s stock valued at $1,394,000 after acquiring an additional 13,560 shares during the period. Institutional investors and hedge funds own 76.27% of the company’s stock.

MET has been the subject of a number of recent research reports. TheStreet upgraded Metlife from a “c+” rating to a “b” rating in a research note on Wednesday, October 4th. ValuEngine downgraded Metlife from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, October 10th. Argus boosted their price objective on Metlife from $55.00 to $60.00 and gave the company a “buy” rating in a research note on Monday, November 6th. Wells Fargo & Co reiterated a “buy” rating on shares of Metlife in a research note on Wednesday, October 18th. Finally, Zacks Investment Research upgraded Metlife from a “hold” rating to a “buy” rating and set a $60.00 price objective for the company in a research note on Thursday, November 9th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $57.77.

In related news, insider Christopher G. Townsend sold 82,731 shares of the business’s stock in a transaction that occurred on Friday, November 3rd. The stock was sold at an average price of $54.60, for a total value of $4,517,112.60. Following the transaction, the insider now directly owns 49,660 shares of the company’s stock, valued at approximately $2,711,436. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Christopher G. Townsend sold 55,712 shares of the company’s stock in a transaction that occurred on Monday, November 6th. The stock was sold at an average price of $54.29, for a total value of $3,024,604.48. Following the sale, the insider now directly owns 25,181 shares in the company, valued at $1,367,076.49. The disclosure for this sale can be found here. 0.32% of the stock is currently owned by insiders.

Metlife Inc (MET) opened at $52.95 on Friday. The company has a quick ratio of 0.16, a current ratio of 0.16 and a debt-to-equity ratio of 0.31. Metlife Inc has a twelve month low of $44.26 and a twelve month high of $55.91. The company has a market capitalization of $55,720.00, a P/E ratio of 115.11, a P/E/G ratio of 1.17 and a beta of 1.49.

Metlife (NYSE:MET) last posted its quarterly earnings results on Wednesday, November 1st. The financial services provider reported $1.09 EPS for the quarter, topping the Zacks’ consensus estimate of $0.90 by $0.19. Metlife had a positive return on equity of 8.81% and a negative net margin of 0.75%. The company had revenue of $16.10 billion for the quarter, compared to analysts’ expectations of $15.47 billion. During the same period in the previous year, the firm earned $1.28 EPS. The firm’s revenue was up 1.7% compared to the same quarter last year. analysts anticipate that Metlife Inc will post 4.42 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 13th. Investors of record on Monday, February 5th will be issued a $0.40 dividend. The ex-dividend date of this dividend is Friday, February 2nd. This represents a $1.60 dividend on an annualized basis and a yield of 3.02%. Metlife’s dividend payout ratio is presently 347.83%.

ILLEGAL ACTIVITY NOTICE: This article was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at https://www.dailypolitical.com/2018/01/19/livforsakringsbolaget-skandia-omsesidigt-sells-6800-shares-of-metlife-inc-met.html.

Metlife Company Profile

MetLife, Inc is a provider of life insurance, annuities, employee benefits and asset management. The Company’s segments include U.S.; Asia; Latin America; Europe, the Middle East and Africa (EMEA); MetLife Holdings, and Corporate & Other. Its U.S. segment is organized into Group Benefits, Retirement and Income Solutions and Property & Casualty businesses.

Want to see what other hedge funds are holding MET? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Metlife Inc (NYSE:MET).

Institutional Ownership by Quarter for Metlife (NYSE:MET)

Receive News & Ratings for Metlife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metlife and related companies with MarketBeat.com's FREE daily email newsletter.